Precision engineering of targeted nanocarriers
© 2018 Wiley Periodicals, Inc..
Since their introduction in 1980, the number of advanced targeted nanocarrier systems has grown considerably. Nanocarriers capable of targeting single receptors, multiple receptors, or multiple epitopes have all been used to enhance delivery efficiency and selectivity. Despite tremendous progress, preclinical studies and clinically translatable nanotechnology remain disconnected. The disconnect in targeting efficacy may stem from poorly-understood factors such as receptor clustering, spatial control of targeting ligands, ligand mobility, and ligand architecture. Further, the relationship between receptor distribution and ligand architecture remains elusive. Traditionally, targeted nanocarriers were engineered assuming a "static" target. However, it is becoming increasingly clear that receptor expression patterns change in response to external stimuli and disease progression. Here, we discuss how cutting-edge technologies will enable a better characterization of the spatiotemporal distribution of membrane receptors and their clustering. We further describe how this will enable the design of new nanocarriers that selectively target the site of disease. Ultimately, we explore how the precision engineering of targeted nanocarriers that adapt to receptor dynamics will have the potential to drive nanotechnology to the forefront of therapy and make targeted nanomedicine a clinical reality. This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Biology-Inspired Nanomaterials > Lipid-Based Structures Biology-Inspired Nanomaterials > Protein and Virus-Based Structures.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology - 10(2018), 5 vom: 23. Sept., Seite e1511 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Deci, Michael B [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Epitopes |
|---|
| Anmerkungen: |
Date Revised 30.03.2022 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/wnan.1511 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM28095154X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM28095154X | ||
| 003 | DE-627 | ||
| 005 | 20231225030518.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/wnan.1511 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0936.xml |
| 035 | |a (DE-627)NLM28095154X | ||
| 035 | |a (NLM)29436157 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Deci, Michael B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Precision engineering of targeted nanocarriers |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 30.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2018 Wiley Periodicals, Inc. | ||
| 520 | |a Since their introduction in 1980, the number of advanced targeted nanocarrier systems has grown considerably. Nanocarriers capable of targeting single receptors, multiple receptors, or multiple epitopes have all been used to enhance delivery efficiency and selectivity. Despite tremendous progress, preclinical studies and clinically translatable nanotechnology remain disconnected. The disconnect in targeting efficacy may stem from poorly-understood factors such as receptor clustering, spatial control of targeting ligands, ligand mobility, and ligand architecture. Further, the relationship between receptor distribution and ligand architecture remains elusive. Traditionally, targeted nanocarriers were engineered assuming a "static" target. However, it is becoming increasingly clear that receptor expression patterns change in response to external stimuli and disease progression. Here, we discuss how cutting-edge technologies will enable a better characterization of the spatiotemporal distribution of membrane receptors and their clustering. We further describe how this will enable the design of new nanocarriers that selectively target the site of disease. Ultimately, we explore how the precision engineering of targeted nanocarriers that adapt to receptor dynamics will have the potential to drive nanotechnology to the forefront of therapy and make targeted nanomedicine a clinical reality. This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Biology-Inspired Nanomaterials > Lipid-Based Structures Biology-Inspired Nanomaterials > Protein and Virus-Based Structures | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a epitopes | |
| 650 | 4 | |a multi-valency | |
| 650 | 4 | |a receptor clustering | |
| 650 | 4 | |a spatial control | |
| 650 | 4 | |a targeted nanocarriers | |
| 700 | 1 | |a Liu, Maixian |e verfasserin |4 aut | |
| 700 | 1 | |a Dinh, Quoc Thai |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Juliane |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology |d 2009 |g 10(2018), 5 vom: 23. Sept., Seite e1511 |w (DE-627)NLM192898752 |x 1939-0041 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2018 |g number:5 |g day:23 |g month:09 |g pages:e1511 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/wnan.1511 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2018 |e 5 |b 23 |c 09 |h e1511 | ||